Novartis Bioventures Ltd 4

4 · Akouos, Inc. · Filed Jul 2, 2020

Form 4Exit

Period: 2020-06-30

Other

Transactions

Conversion
Common Stock
[F1][F2]
2020-06-30+856,262→ 856,262 total(indirect: See Footnote)
Conversion
Common Stock
[F3][F2]
2020-06-30+199,996→ 1,056,258 total(indirect: See Footnote)
Purchase
Common Stock
[F2]
2020-06-30$17.00/sh+125,000$2,125,000→ 1,181,258 total(indirect: See Footnote)
Conversion
Series A Preferred Stock
[F1][F2]
2020-06-30−856,262→ 0 total(indirect: See Footnote)
→ Common Stock (856,262 underlying)
Conversion
Series B Preferred Stock
[F3][F2]
2020-06-30−199,996→ 0 total(indirect: See Footnote)
→ Common Stock (199,996 underlying)

Footnotes (3)

[F1]On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
[F2]Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
[F3]On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Documents

1 file